Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 5/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529611 | 0.81 | MT-CO2 (0.42) | MT-CO2 | |
| SCHEMBL1706045 | 0.80 | FFAR1 (0.41) | FFAR1FFAR4PTGES | |
| SCHEMBL1706741 | 0.78 | FFAR1 (0.53) | FFAR1FFAR4HAO1PTGES | |
| SCHEMBL2138873 | 0.78 | GABRA1 (0.42) | MT-CO2 | |
| SCHEMBL3868314 | 0.77 | CHRNB2 (0.41) | MT-CO2 | |
| SCHEMBL2134821 | 0.77 | GABRG2 (0.37) | MT-CO2 | |
| SCHEMBL3410365 | 0.75 | MT-CO2 (0.39) | MT-CO2 | |
| SCHEMBL977449 | 0.75 | ALDH1A1 (0.42) | MT-CO2 | |
| SCHEMBL3871651 | 0.73 | KDM4E (0.45) | MT-CO2 | |
| SCHEMBL14740797 | 0.73 | RAB9A (0.41) | MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8258316-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | FFAR1 1248/4885FFAR4 1457/4885HAO1 3419/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | FFAR1 1248/4885FFAR4 1457/4885HAO1 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.